Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (November 2018)
27 slides from Genetic Signatures's investor presentation, Nov 26, 2018
Slide 1: AGM Presentation
**DRAFT** AGM Presentation 29 November 2018
Slide 2: Disclaimer
Disclaimer This presentation was prepared by Genetic Signatures Limited known as “Genetic Signatures“, (“GSS” or “the Company”), in order to discuss its business with various interested parties. This presentation in its entirety has been released to the market via the Australian Securities Exchange
Slide 3: Contents
Contents • Year in review 1 • Product overview 2 • Upcoming milestones 3
Slide 4: Corporate summary
Corporate summary Revenue stage healthcare company listed on the ASX Share price (A$) Volume (m) Genetic Signatures Limited (ASX: GSS) 0.80 0.8 A specialist molecular diagnostics company 0.60 0.6 Focused on becoming a global leader in the supply of molecular diagnostic solutions 0.40 0.4 Developing
Slide 5: Board of Directors
Board of Directors Management team with a proven track record in MDx industry and extensive experience in commercialisation of medical devices • Significant experience in leading international sales expansions of biotech companies Nick Samaras • Former Managing Director of Applied Biosystems (acquir
Slide 6: GSS snapshot
GSS snapshot Genetic Signatures is globally commercialising the 3base™ technology which underpins its EasyScreen™ molecular diagnostic kits Genetic Signatures’ 3base™ technology Genetic Signatures EasyScreen™ Portfolio • World-first, proprietary platform technology significantly simplifies genetic dete
Slide 7: Year in Review
Genetic Signatures Transforming Molecular Diagnostics Year in Review
Slide 8: Share price performance
Share price performance Genetic Signatures has made significant operational progress which has been recognised by positive share price perfomance in the last 12 months Share price performance (A$) 0.80 March 2018: +86% April 2018: May 2018: Repeat orders of Alphavirus / European approval (CE-IVD) Fi
Slide 9: Major Australian contract and product launch
Major Australian contract and product launch New domestic customer and product launch creates immediate boost to the domestic revenue base 1 Step change in domestic revenue following Second generation EasyScreen™ product launch and new major contract Respiratory Pathogen Detection Kit - • Sales cont
Slide 10: First sales of ASRs in the US
First sales of ASRs in the US Increasing traction with ASR approach and early revenue out of the US highlights the commercial potential of 3baseTM technology Important milestone for Genetic Signatures Estimated MDx market size (2017, US$)4 • Received its first US sales order of Analyte Specific Reag
Slide 11: Promising clinical trial results
Promising clinical trial results The National CPE Reference Laboratory in Ireland presented successful results from the trial of the EasyScreenTM ESBL & CPO Detection Kit Successful EasyScreenTM ESBL & CPO trial results • The trial was undertaken by Ireland’s National CPO Reference Laboratory • Tria
Slide 12: Strong revenue uplift in 1Q FY19
Strong revenue uplift in 1Q FY19 GSS continues to deliver consistent quarter-on-quarter revenue growth since listing Quarterly revenue (A$k) Key Highlights 1,013 • Despite a relatively soft flu season, +34% Genetic signatures achieved on pcp record quarterly revenues of A$1.0m 754 714 691 677 • Stro
Slide 13: Financial performance
Financial performance Year ending Year ending A$000 30 June 2017 30 June 2018 Other income includes R&D rebates Sales revenue 2,038 2,840 received (A$2.1m in FY2018) and interest received Other income 2,275 2,384 Total revenue 4,313 5,224 Cost of goods sold (602) (1,000) Employee benefits expense
Slide 14: Financial performance - cash
Financial performance - cash Year ending Qtr ending A$000 30 Jun 2018 30 Sep 2018 Receipts from customers 2,902 1,066 Payments to suppliers & employees (8,447) (2,448) Increase in line with sales Interest received 253 4 R&D tax concession received 1,598 - Net cash used in operating activities (3,6
Slide 15: Product overview
Genetic Signatures Transforming Molecular Diagnostics & Product overview
Slide 16: Clear path to global commercialisation for all products
Clear path to global commercialisation for all products Australia EU US Product Trials Pilot stage Registration Registration Ready for ASR FDA trials Clearance and Ready for trials Products development underway revenue2 and sales and sales trials initiated sales EasyScreen™ 2018/2019 2019 Enteric Ex
Slide 17: Product development
Product development High calibre product development team executing on a clear strategy of commercialisation Overview of Genetic Signatures current infectious disease portfolio of 7+ product families1 Revenue focus Enteric Respiratory Undisclosed Alpha/Flavivirus products currently under development
Slide 18: EasyScreen Enteric Detection Kits
EasyScreenTM Enteric Detection Kits Targets 20+ pathogens that affect the intestines and often result in gastroenteritis or other severe illnesses Enteric range overview Pathogen targets • Flagship product is comprised of 3 key kits: • Bacterial targets - targets 6 common Bacterial pathogens includi
Slide 19: EasyScreen Respiratory Pathogen Detection Kit
EasyScreenTM Respiratory Pathogen Detection Kit Respiratory infections represent a substantial global burden in terms of lost productivity and morbidity Respiratory Pathogen Detection Kit overview Pathogen targets • Detection Kit targeting a large addressable market, where • EasyScreenTM Respiratory
Slide 20: EasyScreen ESBL & CPO Detection Kit
EasyScreenTM ESBL & CPO Detection Kit The “superbug” detection kit has advanced rapidly with regulatory approval achieved in the EU and Australia, and trials underway in the US (ASRs) ESBL & CPO Detection Kit overview Pathogen targets • Product was fast-tracked in response to increasing customer • E
Slide 21: EasyScreen STI Detection Kit
EasyScreenTM STI Detection Kit The STI diagnostics market is set for a rapid growth and the simultaneous testing of multiple targets can reduce the spread of infection STI Detection Kit overview Pathogen targets • Innovative STI Detection Kit testing for a range of pathogens • Detects 12 of the most
Slide 22: The science behind 3base technology
The science behind 3base™ technology 3base™ technology reduces complexity in genetic testing, allowing detection of more pathogens. Extra results, higher accuracy, lower cost 3base™ technology 3base™ technology in the detection process 1 3baseTM platform technology Regular cell Lysis and converts or
Slide 23: The EasyScreen competitive advantage
The EasyScreen™ competitive advantage EasyScreen™ offers faster and more effective detection of infectious disease; optimised for high throughput labs High High Rapid time Common Platform throughput specificity to result workflow agnostic Ability to test Superior accuracy Provides optimised Four pro
Slide 24: Powerful evidence of efficacy from clinical trials
Powerful evidence of efficacy from clinical trials Clinical trials demonstrate efficacy St Vincent’s Hospital Evaluation Study results Conventional Evaluation study conducted at Pathogen Methods* EasyScreen™ St. Vincent’s Hospital, Sydney Campylobacter 7 9 Salmonella 8 9 221 patient samples tested a
Slide 25: Upcoming milestones
Genetic Signatures \ Transforming Molecular Diagnostics Upcoming milestones
Slide 26: Multiple upcoming value catalysts
Multiple upcoming value catalysts Objectives Upcoming activities In addition to key upcoming FY19 milestones, GSS will continue to focus on a range of activities delivering value in the near term. Notable activities include: Domestic Europe US Securing new customer TGA approval and CE-IVD registra
Slide 27: Contact us
Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john@geneticsignatures.com Visit us www.geneticsignatures.com Follow us on social media
Genetic Signatures — Investor Presentation (November 2018) on 6ix